CHINA & GERMANY
Research driven pharmaceutical company Boehringer Ingelheim, in partnership with Taizhou China Medical City in Jiangsu Province, China, held a ground-breaking ceremony for a veterinary vaccine manufacturing plant at the China Medical City (Taizhou China Medicine High-Tech Development Zone) last week (Friday, 16 August).
US - Controlling swine diseases such as Porcine Reproductive and Respiratory Syndrome (PRRS), Porcine Circovirus Associated Disease (PCV2) and Mycoplasma pneumonia (M. hyo) is one of the the key challenges for producers and veterinarians. During the 2012 World Pork Expo, swine experts discussed the impacts of these diseases, the latest research and effective ways to manage respiratory diseases on modern production farms.
US - The research driven pharmaceutical company Boehringer Ingelheim will expand its global animal health vaccines business. With the completion of a series of major investments at the US site in St. Joseph, Missouri, the company will further enhance its position in the development and supply of vaccines against the most important diseases of pigs.
Boehringer Ingelheim yesterday announced the expansion of its Animal Health business in China. One of the major moves is the opening of the Asian Veterinary Research & Development (R&D) Center in Zhangjiang, Shanghai.
Milk production is at peak level on day 18 +/- 1 of lactation where up to about 16 litres/day is produced depending on:
Litter size and vitality of the suckling pigs
Genetic potential
Health status
Boehringer Ingelheim DENMARK - Two researchers from Boehringer-Ingelheim Vetmedica in Copenhagen have published a paper showing a highly significant reduction in the use of antimicrobials after vaccination of pigs against porcine proliferative enteropathy in a Danish specific-pathogen-free (SPF) herd.
Hypogalactia is likely to result in malnutrition of suckling pigs.
Get the latest news on Swine Health Subscribe to our newsletter